BellRing Brands (BRBR)
(Delayed Data from NYSE)
$63.19 USD
+0.44 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.18 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.19 USD
+0.44 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.18 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
Zacks News
Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
Child Health in Focus in Face of Delta Strain Threat: 3 Picks
by Urmimala Biswas
Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
by Zacks Equity Research
QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.
Globus Medical (GMED) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.
The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings
BellRing Brands (BRBR) Is Up 5.29% in One Week: What You Should Know
by Zacks Equity Research
Does BellRing Brands (BRBR) have what it takes to be a top stock pick for momentum investors? Let's find out.
4 Safe MedTech Bets Before Delta Strain Disrupts the Market Again
by Urmimala Biswas
Here are four MedTech stocks, HSIC, BRBR, MRVI and EYE, with favorable Zacks Rank and stellar growth parameters.
NEOGEN (NEOG) Enhances Aquaculture Genotyping With New Pact
by Zacks Equity Research
NEOGEN (NEOG) together with CAT can enable members of the aquaculture sector to make more informed breeding decisions.
BellRing Brands (BRBR) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 25.00% and 4.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BellRing Brands (BRBR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BellRing Brands (BRBR) Meets Q1 Earnings Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 0.00% and 4.38%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Earnings Season Could Be Great for BellRing Brands (BRBR)
by Zacks Equity Research
BellRing Brands (BRBR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.